SD Biosensor Inc
KRX:137310
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (0.8), the stock would be worth ₩-477.77 (106% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -13.5 | ₩8 550 |
0%
|
| 3-Year Average | 0.8 | ₩-477.77 |
-106%
|
| 5-Year Average | 1.8 | ₩-1 128.68 |
-113%
|
| Industry Average | 13.9 | ₩-8 794.21 |
-203%
|
| Country Average | 8.5 | ₩-5 400 |
-163%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₩945.7B
|
/ |
Oct 2025
₩-63.7B
|
= |
|
|
₩945.7B
|
/ |
Dec 2025
₩78.7B
|
= |
|
|
₩945.7B
|
/ |
Dec 2026
₩115.5B
|
= |
|
|
₩945.7B
|
/ |
Dec 2027
₩168.4B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
SD Biosensor Inc
KRX:137310
|
1T KRW | -13.5 | 9 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60.7B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 27.9 | 38.5 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.4B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
95.4B DKK | 12.6 | 23.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD | 14.4 | 33.2 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.4B GBP | 11.6 | 33.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 16.8 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
880.1B JPY | 23.5 | 49.8 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -81.4 | -36.4 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 14.7 | 22.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
SD Biosensor Inc
Glance View
SD Biosensor, Inc. develops and manufactures cholesterol, blood glucose testing and monitoring equipment. The company is headquartered in Suwon, Gyeonggi-Do. The company went IPO on 2021-07-16. The firm is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The firm is engaged in the research, development and sale of products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, enzyme immunological reaction diagnosis products and others. The firm distributes its products within domestic market and to overseas markets.
